Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
Get Alerts CNTA Hot Sheet
Join SI Premium – FREE
BOSTON and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences:
Event: Guggenheim Healthcare Innovation Conference
Date: November 13, 2024
Location: Boston, MA
Fireside Chat: 9:00 AM ET
Event: Jefferies London Healthcare Conference
Date: November 19, 2024
Location: London, UK
Fireside Chat: 1:30 PM GMT
Event: 7th Annual Evercore HealthCONx Conference
Date: December 5, 2024
Location: Miami, FL
Fireside Chat: 10:00 AM ET
Access to the live webcasts of these events, as well as archived recordings, will be available under the “Events and Publications” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients. Our most advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on our LockBody® technology platform. We operate with the conviction that each of our programs has the potential to change the current treatment paradigm and establish a new standard of care. For more information, visit www.centessa.com, which does not form part of this release.
Contact:
Kristen K. Sheppard, Esq.
SVP of Investor Relations
[email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ChowChow Cloud International Holdings Limited Provides Response to Unusual Market Action
- KSMModel.ai Launches the First Platform Built on a Unified Framework for AI Citation Visibility
- Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Jefferies & Co, GuggenheimSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share